This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement / Goldsmith, D., Covic, A., Vervloet, M., Cozzolino, M., Nistor, I., Brandenburg, V., Bover, J., Evenepoel, P., Massy, Z., Mazzaferro, S., Urena-Torres, P., Abramowicz, D., Bolignano, D., Cannata Andia, G., Cochat, P., Delvecchio, L., Drechsler, C., Eckardt, K.U., Fouque, D., Fox, J., et al.. - In: NEPHROLOGY DIALYSIS TRANSPLANTATION. - ISSN 0931-0509. - 30:5(2015), pp. 698-700. [10.1093/ndt/gfv050]
Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement
Mazzaferro S.Membro del Collaboration Group
;
2015
Abstract
This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.| File | Dimensione | Formato | |
|---|---|---|---|
|
Goldsmith_Should_2015.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
109.57 kB
Formato
Adobe PDF
|
109.57 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
